Zura Bio

Historical price data

Zura Bio's mission is to dramatically improve the lives of patients with severe autoimmune and inflammatory conditions by developing novel medicines based on dual-pathway antagonism. Since its 2022 founding, the company has rapidly built a promising clinical pipeline through the strategic in-licensing of three assets from Eli Lilly and Pfizer, culminating in a public listing via SPAC merger in 2023. With a seasoned leadership team and over $400 million raised to date, Zura is advancing its lead candidate, tibulizumab, through Phase 2 proof-of-concept studies, positioning itself as a capital-efficient disruptor in the autoimmune therapeutics space.

A development platform centered on dual-pathway antagonism, hypothesizing that simultaneous inhibition of two distinct immune pathways yields superior efficacy in complex autoimmune diseases compared to single-pathway inhibition.

In systemic sclerosis, tibulizumab competes with approved therapies (Actemra, Ofev) and novel pipeline agents, differentiated by its unique IL-17A/BAFF dual inhibition. In hidradenitis suppurativa, it faces established anti-IL-17 leaders like Cosentyx and Bimzelx, aiming to show improved efficacy via added BAFF blockade.